Abstract 399: Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm
Authors: Pyke Rachel Marty , Mellacheruvu Datta , Abbott Charles , Dea Steven , Levy Eric , Zhang Simo V. , Bedi Nikita , Colevas A. Dimitrios , Bhave Devayani , Chinnappa Manju , Bartha Gabor , Lyle John , West John , Snyder Michael , Sunwoo John , Chen Richard , Boyle Sean Michael 
Published: July 2021

Abstract
HLA loss of heterozygosity (LOH) is increasingly being recognized as an important immune escape mechanism in response to checkpoint inhibitor therapy. HLA LOH reduces the repertoire of neoantigens displayed on the cell surface of cancer cells, limiting the efficacy of the immune system to detect and eliminate them. Though highly accurate HLA LOH detection algorithms are needed to allow clinical utility, the field lacks robust, allele-specific validation approaches. Moreover, algorithms of unknown sensitivity and specificity have led to significant discrepancies in the estimated occurrence of HLA LOH as an immune escape mechanism across tumor types. To address these challenges, we have developed a machine learning algorithm to detect HLA LOH (DASH - Deletion of Allele-Specific HLAs), established the accuracy of the algorithm with an allele-specific PCR validation strategy, investigated the frequencies of HLA LOH across 14 tumor types in a cohort of over 800 patients and observed allele-specific neoantigen expansion in response to immunotherapy. To build DASH, we profiled 279 patients on the ImmunoID NeXT Platform to create a training dataset. Our novel features, which account for allele-specific differences in exome probe capture and capitalize on our whole exome platform by including information about copy number alterations in the regions flanking the HLA genes, were used to train an XGBoost model. Orthogonal, allele-specific validation was required to accurately assess sensitivity and specificity for clinical utility. Thus, we profiled over 30 paired tumor-normal cell lines on the ImmunoID NeXT Platform® and identified cell lines with HLA LOH. Using in silico mixtures, we found 100% sensitivity and specificity for tumors with at least 36% tumor purity. Next, we designed a digital PCR (dPCR) assay using patient-specific, allele-specific primers that target a single HLA allele while avoiding all other HLA alleles and tested the limit of detection of the assay in the same cell lines. Then, we performed dPCR with patient-specific primers on 20 tumor and normal sample pairs and found 94% sensitivity. After establishing the high sensitivity and specificity of DASH, we profiled over 800 patients spanning 14 tumor types on the ImmunoID NeXT Platform. We found that over 25% of patients in the majority of tumor types had at least one HLA LOH event. Further, we observed that novel neoantigens that arose during checkpoint treatment were significantly more likely to bind to deleted HLA alleles as compared to the remaining HLA alleles in a head and neck carcinoma cohort treated with anti-PD-1 therapy, shedding light on the mechanism of immune escape in response to checkpoint inhibitors. In summary, we introduced an HLA LOH detection method, performed allele-specific validation, exposed widespread HLA across tumor types and observed the mechanism of immune escape in response to immunotherapy.
Citation Format: Rachel Marty Pyke, Datta Mellacheruvu, Charles Abbott, Steven Dea, Eric Levy, Simo V. Zhang, Nikita Bedi, A. Dimitrios Colevas, Devayani Bhave, Manju Chinnappa, Gabor Bartha, John Lyle, John West, Michael Snyder, John Sunwoo, Richard Chen, Sean Michael Boyle. Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 399.